IL2 and neoplasm: Anti-tumor immune reactivity has also been shown to be subject to cytokine (type I and II IFNs, IL-2, IL-7, IL-12, IL-15, IL-18, and IL-21) regulation and augmentation in preclinical and clinical settings.